Icon
+91 94997 68112
Login Register

Venclexta - (10,50,100 mg; Tablet, Oral)

Venetoclax Abbvie
10,50,100 mg; Tablet, Oral
More Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
None None
VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate
Yes
*** *********** ******* ** **** ***** **** ** *****'* *** ******* *** ****. ** ***** * **** ** ** ******* '***, '***, '*** *** *** *********. ******* ***** * **** ** ** ****** '*** *** *** *********. ** ****** **** **** *** ****** ** *** ****.
Venclexta Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11
** *****'* ********* ********* ********* *** ********* ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** ********* *** ********* **** ** *** **, ****
******* *** ********* ********* *** ********* *** ********* ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** ********* *** ********* **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
** *****'* *** \ ********* *** **, **** ******* **** *** ****** *** ****
******* *** \ ********* *** **, **** ******* **** *** ****** *** ****
  1. *** **, **** : ** *****'* ******** ****** ***** **'* **** ** ****** ** ******* '***, '*** *** '***
  2. *** **, **** : ******* ******** ****** ***** **'* **** ** ****** ** ****** '***
  3. *** **, **** : ****** ***** * **** ******* ** *****'* ** ******* '***, '*** *** '***.
  4. *** **, **** : ****** ***** * **** ******* ******* ** ****** '***
  5. *** **, **** : ****** ***** ***** ******* ********* ******* *******, ***** **** **** ************ ** ****** '*** (*** **, ****)
  6. *** **, **** : ****** ***** ***** ******* ********* ******* **. *****'*, ***** **** **** ************ ** ****** '*** (*** **, ****)
  7. *** **, **** : ****** ***** * ****** ******* ********* ******* **. *****'* ***** **** **** ******* '***, '*** *** *** ** ****** '***
  8. *** **, **** : ****** ***** ****** ******* ********* ******* *******, ***** **** **** ************ ** ******* '***, '*** *** *** ** ****** '***
  9. *** *, **** : ****** ***** * ***** ******* ********* ******* ******* *** **. *****'* ***** **** **** ************ ** ****** '*** (*** **, ****)
  10. *** **, **** : ****** ***** * ****** ******* ********* ******* ******* *** **. *****'* ***** **** **** ************ ** ******* '***, '***, '***, *** '***. *** ***** ******** ****** *** ***** ********* **** *** ***********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.